首页> 外文期刊>Clinical infectious diseases >Investing in Immunity: Prepandemic Immunization to Combat Future Influenza Pandemics
【24h】

Investing in Immunity: Prepandemic Immunization to Combat Future Influenza Pandemics

机译:投资免疫:大流行前免疫以应对未来的流感大流行

获取原文
获取原文并翻译 | 示例
           

摘要

We are unlikely, with current technologies, to have sufficient pandemic influenza vaccine ready in time to impact the first wave of the next pandemic. Emerging data show that prior immunization with an immunologically distinct hemagglutinin of the same subtype offers the potential to "prime" recipients for rapid protection with a booster dose, years later, of a vaccine then manufactured to match the pandemic strain. This article proposes making prepandemic priming vaccine(s) available for voluntary use, particularly to those at high risk of early occupational exposure, such as first responders and healthcare workers, and to others maintaining critical infrastructure. In addition to providing faster protection and potentially reducing social disruption, being able, early in a pandemic, to immunize those who had received prepandemic vaccine with one dose of the pandemic vaccine, rather than the 2 doses typically required, would reduce the total doses of pandemic vaccine then needed, extending vaccine supplies.
机译:使用当前的技术,我们不太可能及时准备足够的大流行性流感疫苗来影响下一次大流行的第一波。新兴数据表明,事先用相同亚型的免疫学上不同的血凝素进行免疫接种,有可能“增强”接受者的免疫力,从而在几年后以加强剂量快速接种疫苗,然后再生产与大流行毒株匹配的疫苗。本文建议使大流行前启动疫苗可以自愿使用,特别是对那些具有早期职业暴露高风险的人(例如急救人员和医护人员)以及维护关键基础设施的其他人。除了提供更快的保护并可能减少社会破坏外,在大流行初期能够用一剂大流行疫苗而不是通常所需的两剂疫苗为接种大流行前疫苗的人免疫。然后需要大流行疫苗,扩大疫苗供应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号